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Abstract
AIM: To elucidate risk factors associated with dyspla-
sia of short-segment Barrett’s esophagus (BE).
METHODS: A total of 151 BE patients who underwent 
endoscopic examination from 2004 to 2008 in Aoyama 
Hospital, Tokyo Women’s Medical University, Japan and 
whose diagnosis was confirmed from biopsy specimens 
were enrolled in the study. BE was diagnosed based 
on endoscopic findings of gastric-appearing mucosa 
or apparent columnar-lined esophagus proximal to the 
esophagogastric junction. Dysplasia was classified into 
three grades - mild, moderate and severe - according 
to the guidelines of the Vienna Classification System 
for gastrointestinal epithelial neoplasia. Anthropometric 
and biochemical data were analyzed to identify risk fac-
tors for BE dysplasia. The prevalence of Helicobacter 
pylori  (H. pylori ) infection and the expression of p53  by 
immunohistological staining were also investigated.
RESULTS: Histological examination classified patients 
into three types: specialized columnar epithelium (SCE) 
(n  = 65); junctional (n  = 38); and gastric fundic (n  
= 48). The incidence of dysplasia or adenocarcinoma 
from BE of the SCE type was significantly higher than 
that of the other two types (P  < 0.01). The univariate 
analysis revealed that sex, H. pylori  infection, body 
weight, p53  overexpression, and low diastolic blood 
pressure (BP) were associated with BE dysplasia. In 
contrast, body mass index, waist circumference, meta-
bolic syndrome complications, and variables related to 
glucose or lipid metabolism were not associated with 
dysplasia. Multivariate logistic analysis showed that 
overexpression of p53  [odds ratio (OR) = 13.1, P  = 
0.004], H. pylori  infection (OR = 0.19, P  = 0.066), and 
diastolic BP (OR = 0.87, P  = 0.021) were independent 
risk factors for epithelial dysplasia in BE patients with 
the SCE type.
CONCLUSION: Overexpression of p53  is a risk factor 
for dysplasia of BE, however, H. pylori  infection and di-
astolic BP inversely associated with BE dysplasia might 
be protective.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Barrett’s esophagus (BE) is known to be a 
precancerous state of adenocarcinoma will become 
common in Asian countries, therefore, it is important 
to establish a high-risk group or strategy for screening 
or follow-up of BE. We present here the results of uni-
variate and multivariate analysis to identify variables 
associated with dysplasia of BE. p53  expression in im-
munohistochemistry was associated with dysplasia, 
and Helicobacter pylori  infection and high diastolic 
blood pressure may act as protective factors against 
dysplastic change of BE. These three factors may be 
candidates to establish a high-risk group for esopha-
geal adenocarcinoma.
Fujita M, Nakamura Y, Kasashima S, Furukawa M, Misaka R, 
Online Submissions: http://www.wjgnet.com/esps/
bpgoffice@wjgnet.com
doi:10.3748/wjg.v20.i15.4353
World J Gastroenterol  2014 April 21; 20(15): 4353-4361
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
Risk factors associated with Barrett’s epithelial dysplasia
Mikiko Fujita, Yuri Nakamura, Saeko Kasashima, Maiko Furukawa, Ryoichi Misaka, Hikaru Nagahara
Fujita M et al . Risk factors for Barrett’s epithelial dysplasia
Nagahara H. Risk factors associated with Barrett’s epithelial dys-
plasia. World J Gastroenterol 2014; 20(15): 4353-4361  Available 
from: URL: http://www.wjgnet.com/1007-9327/full/v20/
i15/4353.htm  DOI: http://dx.doi.org/10.3748/wjg.v20.i15.4353
INTRODUCTION
Barrett’s esophagus (BE) is defined as a condition in 
which normal squamous mucosa is replaced by colum-
nar epithelium. This intestinal metaplasia of  the distal 
esophagus is considered to be a premalignant condition 
where metaplasia may progress to dysplasia and subse-
quently to adenocarcinoma[1-6]. BE is generally regarded 
as a complication of  chronic and severe gastroesopha-
geal reflux disease (GERD). Elevation of  the intra-
abdominal pressure by obesity is a factor contributing to 
GERD, suggesting that obesity is a risk factor for BE[7-10]. 
GERD and BE appear to be metabolic syndrome (MS)-
related complications, given that waist circumference, 
obesity, and body mass index (BMI) are associated with 
GERD[11-16].
Moreover, Helicobacter pylori (H. pylori) infection may 
play a key role in suppression of  BE. Two main inhibit-
ing roles for development of  BE have been postulated 
in H. pylori infection: H. pylori-induced atrophic gastritis 
resulting in less gastric acid secretion; and neutralization 
of  the gastric acid by ammonia produced by H. pylori 
independently of  gastric atrophy[17-23]. Cag-A positive H. 
pylori infection is strongly associated with a reduced risk 
of  esophageal adenocarcinoma, and the association is 
independent of  gastric atrophy, suggesting the involve-
ment of  a mechanism other than reduced acidic gastric 
reflux[24-26]. In Japan, the prevalence of  H. pylori is declin-
ing and it can be easily eradicated; however, it remains 
uncertain whether the incidence of  BE will increase or 
decrease as a consequence of  the low prevalence of  H. 
pylori infection[27,28].
BE is characterized by three types of  columnar epi-
thelium, namely, cardiac type (junctional type), fundic 
type, and intestinal metaplasia type [specialized columnar 
epithelium type (SCE) type]. It has been shown that 
there is a high incidence of  adenocarcinoma in the distal 
esophagus arising from SCE in patients with BE[29,30].
BE is classified as either long-segment type (length ≥ 
3 cm) or short-segment type (length < 3 cm). In western 
countries, long-segment Barrett’s esophagus (LSBE) is 
more prevalent, while short-segment Barrett’s esophagus 
(SSBE) is more common, and the incidence of  adeno-
carcinoma arising from SSBE is steadily increasing in 
Japan[27,28,31-33].
Several studies have shown that most patients with 
BE do not progress to cancer, although some do[1-3,29,30]. 
Thus, it is important to determine how BE progresses 
to dysplasia and adenocarcinoma and to identify the type 
of  BE patients who may have a possibility of  malignant 
transformation in SCE. It has been reported that central 
adiposity, metabolic syndrome, and high BMI are associ-
ated with BE and adenocarcinoma[10-16]. In this study, we 
investigated the risk factors associated with BE dysplasia.
MATERIALS AND METHODS
Study population
A total of  151 patients (105 male, 46 female) with his-
tologically diagnosed BE were enrolled. All cases were 
incident cases and enrolled in a consecutive series from 
April 2004 to March 2008. Patients who had received 
antibiotics, steroids, or nonsteroidal anti-inflammatory 
drugs were excluded from the study. Patients were also 
excluded if  they had peptic ulcer, underwent partial gas-
trectomy, consumed alcohol excessively, or had comor-
bid diseases such as liver cirrhosis and uremia. Written 
informed consent was obtained from all patients.
Endoscopic examination
BE was diagnosed based on endoscopic findings of  
gastric-appearing mucosa or apparent columnar lined 
esophagus proximal to the esophagogastric junction. The 
esophagogastric junction was defined as the pinch at the 
end of  the tubular esophagus coinciding with the proxi-
mal margin of  the gastric folds of  the hiatal hernia. BE 
was defined as columnar mucosa proximal to the distal 
ends of  esophageal longitudinal palisading vessels accord-
ing to the Japanese Society of  Esophageal Disease[34,35]. 
These veins are visible endoscopically when a conscious 
patient takes a deep breath.
SSBE was defined as an epithelium length < 3 cm 
and LSBE as an epithelium length > 3 cm, as described 
previously[1,2,29,30] The length of  BE were measured by 
measuring forceps (Olympus, Tokyo, Japan).
When abnormal columnar mucosa characteristics 
such as erosions, red flares, elevated regions, or mucosal 
breaks were observed between the proximal limit of  
the gastric folds and squamous epithelium, we detected 
metaplastic change by chromoendoscopy and staining 
mucosa with crystal violet (Figure 1A, B). For chro-
moendoscopy 200000 U pronase (Pronase MS; Kaken 
Pharmaceutical Co., Matsumoto, Japan) dissolved in 300 
mL warm water was sprayed around the esophagogastric 
junction area with a spray tube, and a 0.03% solution of  
crystal violet was applied to the same area. A few min-
utes later, the sprayed area was washed thoroughly with 
water. When mucosa showing a tubular or villous pit 
pattern, which is typical of  SCE in BE, was observed in 
the esophagogastric junction, we performed a targeted 
biopsy in that area. BE was confirmed by histological 
findings from biopsy specimens in all patients.
Histology
All biopsy specimens were fixed in formalin, embed-
ded in paraffin, sectioned, mounted on slides and then 
stained with hematoxylin and eosin using standard tech-
niques. Dysplasia was classified into three grades: mild, 
moderate and severe, according to the guidelines of  the 
Vienna Classification System for gastrointestinal epithe-
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lial neoplasia[17,36]. To perform immunohistological stain-
ing of  p53, an anti-human p53 antibody (DO-7 mouse 
monoclonal antibody, IR616; Dako, Denmark) was used 
according to the manufacturer’s protocol. The expres-
sion level of  p53 protein was determined and graded 
based on the intensity of  nuclear staining in columnar 
cells as follows: no staining (-), positive nuclear staining 
in 5%-10% of  cells (+), and positive nuclear staining in 
> 10% of  cells (++), according to the work of  Keswani 
et al[37] (Figure 2). All biopsy specimens were examined 
by an experienced gastrointestinal pathologist.
H. pylori infection
The presence of  gastric H. pylori was determined based 
on the results of  Giemsa and/or Steiner’s silver staining 
in a minimum of  three gastric surveillance biopsies (one 
each obtained from the antral greater curvature, greater 
curvature of  the mid to distal body, and lesser curvature 
in the proximal body). H. pylori colonization was assessed 
by an experienced pathologist blinded to the clinical 
data. Patients who were not confirmed H. pylori infection 
by using above histological analysis were retested by oth-
er methods. We confirmed H. pylori negativity by com-
bination of  serum HP-specific antibody test with 13C-
urea breath test or H. pylori antigen test in the stools.
Anthropometry and blood pressure
The body weights of  patients, while not wearing heavy 
outdoor clothing or shoes, was measured to the near-
est 0.1 kg using a digital scale. Height (barefoot) was 
measured using a portable stadiometer. Waist circumfer-
ence was measured to the nearest 0.1 cm using a plastic 
tape just above the umbilical portion while standing in 
a relaxed position after gentle expiration. BMI was cal-
culated as weight in kilograms divided by the square of  
height in meters (kg/m2). Blood pressure was measured 
with a mercury sphygmomanometer on each arm after at 
least 10 min of  rest.
Definition of MS and biochemical analysis
MS was diagnosed according to the criteria set out by 
the Japanese Committee for the Diagnostic Criteria of  
Metabolic Syndrome[38]: central obesity (waist circumfer-
ence ≥ 85 cm Japanese men, ≥ 90 cm Japanese women) 
plus any two of  the following; raised triglycerides ≥ 150 
mg/dL or specific treatment for this lipid abnormality; 
reduced high density lipoprotein (HDL)-cholesterol < 40 
mg/dL in men and women; raised blood pressure (sys-
tolic ≥ 130 mmHg or diastolic ≥ 85 mmHg) or treat-
ment of  hypertension; fasting glucose ≥ 110 mg/dL or 
previously diagnosed type 2 diabetes mellitus.
After a 12-h overnight fast, venous blood samples 
were taken for the standard biochemical data.
Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows version 17.0 (SPSS, Tokyo, Japan). Results for con-
tinuous variables were expressed as mean ± SD for each 
subject group. The statistical difference was determined 
by two-sided Student’s t test (for equal variance cases) or 
Welch’s t test (for unequal variance cases). Non-normally 
distributed variables were compared by the Mann-Whit-
ney U test. Variables given as proportions were com-
pared using the c2 test. The relationships between risk 
factors and dysplasia including adenocarcinoma of  BE 
were examined by multivariate logistic regression analy-
sis. p < 0.05 was considered to be statistically significant. 
Differences in mean laboratory data and anthropometric 
data across three categories were evaluated using one-
way analysis of  variance (ANOVA).
RESULTS
Endoscopic findings of BE by crystal violet staining
Crystal violet staining was performed when we recognized 
BE during routine endoscopic examination. The intestinal 
metaplastic lesion was stained with a violet color, resulting 
in easy recognition of  the targeted biopsy (Figure 1A, B).
Dysplasia in SCE-type BE
The average age of  the 151 BE patients was 62.9 ± 10.6 
years and there were 105 men to 46 women (ratio 2.3:1). 
The demographic characteristics of  the patients accord-
ing to pathological classification are shown in Table 1. 
BE patients were classified into three categories: SCE 
type (n = 65), junctional type (n = 38), and gastric fundic 
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Figure 1  Barrett’s esophagus stained by crystal violet. A: Regular observation of Barrett’s esophagus; B: Staining with crystal violet in the same region.
A B
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type (n = 48), and the incidence of  dysplasia in these 
three groups was 30.8% (20/65), 7.9% (3/38) and 4.2% 
(2/48), respectively. The ratio of  dysplasia in patients 
with SCE-type BE was significantly higher than in pa-
tients with junctional- and gastric-fundic-type BE (p = 
0.02 and p = 0.002, respectively).
Variables associated with dysplasia in SCE-type BE
We focused on the SCE type of  BE because of  the high 
rate of  dysplastic change associated with this condition, 
as shown in Table 1. We compared variables between 
SCE-type BE patients with and without dysplasia (Table 
2). H. pylori infection, p53 overexpression (Figure 2), body 
weight, and diastolic BP were identified as risk factors 
strongly associated with dysplastic change. In contrast, 
BMI, waist circumference, MS complications, and vari-
ables related to glucose or lipid metabolism were not 
associated with dysplasia. We then conducted multivari-
ate logistic analysis of  those variables that showed low p 
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40 ×, HE 40 ×, p53
Figure 2  Immunostaining of p53. The upper panel shows hematoxylin and eosin staining and the lower panel shows immunostaining of p53 using the identical 
sample. A: (-), no p53 expression; B: (+), moderate p53 expression characterized by positive nuclear staining in 5%-10% of cells; C: (++), high p53 expression charac-
terized by positive nuclear staining in > 10% of cells.
Table 1  Characterization of the three types of Barrett’s esophagus
Specialized columnar P  value
Epithelium type Junctional type Gastric fundic type
(n  = 65) (n  = 38) (n  = 48)
Sex 52/13 10/28 25/23   0.005
Age (yr) 62.9 ± 10.6 65.0 ± 8.2 58.8 ± 11.9 0.07
Dysplasia 20/65 (30.8%) 3/38 (7.9%) 2/48 (4.2%)   0.003
A
40 ×, HE 40 ×, p53
B
40 ×, HE 40 ×, p53
C
No dysplasia, p53  (-)
Moderate dysplasia, p53  (+)
Adenoca., p53  (++)
Fujita M et al . Risk factors for Barrett’s epithelial dysplasia
Table 3  Multivariate analysis of variables associated with Bar-
rett’s epithelial dysplasia
Table 2  Univariate analysis of variables associated with Barrett’s epithelial dysplasia
values in the univariate analysis shown in Table 2; namely, 
sex, H. pylori infection, body weight, p53 overexpression, 
and low diastolic BP. Among these these variables, p53 
overexpression, H. pylori infection, and low diastolic BP 
were independent risk factors associated with dysplasia 
complicated in patients with BE of  the SCE type (Table 3). 
The p value of  H. pylori infection was 0.066 (not less than 
0.05), but the odds ratio was 0.187, which seemed to give 
a relatively strong effect on the association with Barrett 
epithelial dysplasia. Thus, we included it in Table 3.
Risk factors associated with progression of SCE from 
nondysplastic epithelium to low-grade and high-grade 
dysplasia
We assesed the linearity of  the relationship between risk 
factors and progression. We classified dysplasia into three 
groups: no dysplasia (n = 45), low-grade dysplasia (n = 
14), and high-grade dysplasia (n = 6) including adenocar-
cinoma (Table 4). Based on ANOVA, six variables were 
significantly associated with alteration of  SCE from non-
dysplasia to high-grade dysplasia: length of  BE, H. pylori 
infection, p53 overexpression, body weight, GERD, and 
low diastolic BP. Only two of  these six variables showed 
a linear correlation with alteration to high-grade dysplasia; 
that is, H. pylori infection and p53 overexpression (Table 4).
Correlation between p53 expression and progression 
of SCE from non-dysplasia to low- and high-grade 
dysplasia
Given the strong association observed between p53 over-
expression and dysplasia seen in the multivariate logistic 
analysis (Table 3), we analyzed the level of  p53 expression 
and its association with progression of  nondysplastic 
SCE to low- and high-grade dysplasia including adeno-
carcinoma. The expression of  p53 was categorized as 
no expression (-), moderate expression characterized by 
positive nuclear staining in 5- 10% of  cells (+), and high 
expression, characterized by positive nuclear staining in 
> 10% of  cells (++) (Figure 2). As shown in Table 5, 
only 10% of  patients in the nondysplastic SCE group ex-
pressed p53 at a low level, whereas expression was high in 
the group with high-grade dysplasia (p < 0.01).
DISCUSSION
Several studies, based on endoscopic, biochemical and 
anthropometric data, have identified GERD, absence of  
H. pylori infection, MS, waist circumference, and body 
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Normal (n  = 45) Dysplasia (n  = 20) P  value OR 95%CI
Sex (male/female) Dec-33 19/1   0.073   0.145 0.017-1.202
Age (yr) 65.0 ± 9.8   64.2 ± 11.3   0.730   0.991 0.940-1.044
Length of BE (SSBE/LSBE) Feb-43 18/2   0.402   2.389   0.312-18.294
H. pylori infection rate   34/9 (2) 7/12 (1)    0.0021   0.154 0.047-0.506
p53 positive rate 4/41 13/7 < 0.0011 19.036   4.800-75.499
Body weight (kg) 61.0 ± 9.7   68.2 ± 10.6   0.019   1.081 1.013-1.154
BMI (kg/m2) 23.1 ± 2.8 23.7 ± 3.2   0.451   1.074 0.891-1.295
Waist circumference (cm) 86.9 ± 7.9 88.4 ± 9.0   0.585   1.022 0.945-1.105
GERD 19/26 9/11   0.835   1.120 0.387-3.235
Hypertension (BP > 130/85) 29/14 (2) 9/10 (1)   0.094   0.395 0.133-1.172
Systolic BP (mmHg) 127 ± 16 121 ± 16   0.264   0.980 0.946-1.015
Diastolic BP (mmHg)   76 ± 10 69 ± 8   0.009   0.907 0.843-0.976
Diabetes 14/25 (6) 10/9 (1)   0.188   2.071 0.701-6.124
Fasting blood glucose (mg/dL) 118 ± 32 111 ± 19   0.447   0.992 0.971-1.013
HbA1c (%)   5.6 ± 1.0   5.5 ± 0.7   0.804   0.919 0.470-1.798
Dyslipidemia 24/19 (2) 11/8 (1)   0.322   0.576 0.193-1.715
TG (mg/dL) 144 ± 58 139 ± 98   0.807   0.999 0.991-1.007
TC (mg/dL) 202 ± 30 189 ± 33   0.141   0.987 0.969-1.005
HDL-C (mg/dL)   55 ± 13 53 ± 9   0.850   0.996 0.950-1.043
LDL-C (mg/dL) 118 ± 26 107 ± 30   0.152   0.985 0.964-1.006
Fatty liver   17/13 (15)   6/8 (6)   0.395   0.574 0.159-2.066
γ-GT (U/L)    55 ± 48   59 ± 77   0.781   1.001 0.992-1.011
AST (IU/L) 24 ± 8   25 ± 10   0.769   1.009 0.948-1.075
ALT (IU/L)   24 ± 15   24 ± 12   0.906   0.998 0.958-1.039
hs-CRP (mg/dL)   0.107 ± 0.142   0.101 ± 0.116   0.890   0.706   0.005-98.830
MS   15/14 (16)   6/8 (6)   0.586   0.700 0.194-2.530
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BP: Blood pressure; GT: Glutamyl transpeptidase; HbA1c: Hemoglobin A1c; HDL-C: 
High-density lipoprotein cholesterol; hs-CRP: High sensitivity C-reactive protein; LDL-C: Low-density lipoprotein cholesterol; TG: Triglyceride; TC: Total 
cholesterol; H. pylori: Helicobacter pylori.
Risk factor P  value OR 95%CI
p53 0.004 13.107   2.275-75.504
H. pylori 0.066   0.187 0.031-1.116
Diastolic BP 0.021   0.874 0.780-0.980
Fujita M et al . Risk factors for Barrett’s epithelial dysplasia
H. pylori: Helicobacter pylori; BP: Blood pressure.
Table 4  Analysis of variance for the three categories of Barrett’s epithelium: non-dysplasia, low-grade dysplasia, and high-grade dysplasia
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No dysplasia (n  = 45) Low grade (n  = 14) High grade (n  = 6) P  value
Sex (male/female) Dec-33 13/1 6/0    0.177
Age (yr) 65.0 ± 9.8   64.3 ± 12.4   63.8 ± 9.4    0.941
Length of BE (SSBE/LSBE) Feb-43 14/0 4/2    0.044
H. pylori infection rate Sep-34 6/7 1/5    0.002
p53 positive rate 4/41 7/7 6/0 < 0.001
Body weight (kg) 61.0 ± 9.7 69.5 ± 9.8     65.5 ± 12.5    0.033
BMI (kg/m2) 23.1 ± 2.8 24.0 ± 3.1   23.3 ± 3.7    0.689
Waist circumference (cm) 86.9 ± 7.9 88.1 ± 9.6   89.3 ± 8.4    0.848
GERD 19/26 9/5 0/6    0.020
Hypertension (BP > 130/85) 29/14 6/7 3/3    0.155
Systolic BP (mmHg) 127 ± 16 120 ± 19 125 ± 6    0.473
Diastolic BP (mmHg)   76 ± 10 69 ± 9   71 ± 6    0.016
Diabetes 14/25 7/6 3/3    0.425
Fasting blood glucose (mg/dL) 118 ± 32 113 ± 19   108 ± 20    0.712
HbA1c (%)   5.6 ± 1.0   5.5 ± 0.7     5.5 ± 0.8    0.971
Dyslipidemia 24/19 5/8 3/3    0.612
TG (mg/dL) 144 ± 58 118 ± 71     183 ± 137    0.190
TC (mg/dL) 202 ± 30 195 ± 36   174 ± 25    0.124
HDL-C (mg/dL)   55 ± 13 55 ± 9   48 ± 7    0.407
LDL-C (mg/dL) 118 ± 26 112 ± 33     97 ± 17    0.201
Fatty liver 17/13 5/7 1/1    0.744
γ-GTP (U/L)   55 ± 48   40 ± 31     101 ± 126    0.097
AST (IU/L) 24 ± 8   26 ± 10     24 ± 10    0.837
ALT (IU/L)   24 ± 15   25 ± 13     21 ± 10    0.803
Hs-CRP (mg/dL)   0.107 ± 0.142   0.104 ± 0.126     0.084 ± 0.029    0.973
Metabolic syndrome 15/14 4/7 2/1    0.604
Table 5  Relationship between the level of p53  expression 
and grade of dysplasia
weight as risk factors associated with the presence of  
BE[7-16]. One of  the most notable findings from epide-
miological reports has been a strong inverse association 
between H. pylori infection and dysplasia of  Barrett’s epi-
thelium[17,18,21-26].
Esophageal adenocarcinoma derived from BE is not 
common in Japan as compared with western countries, 
whereas gastric carcinoma is more prevalent in Japan. 
This inverse relationship may reflect the high prevalence 
of  H. pylori infection in Japan and the low prevalence in 
western countries[24,39,40].
Another notable epidemiological difference between 
these regions is the length of  BE; that is, SSBE is com-
mon in Japan but LSBE is more prevalent in western 
countries[27,28,30,31]. The underlying reasons for this differ-
ence are not currently known.
Here, we identified risk factors associated with the 
presence of  BE dysplasia by comparison of  patients with 
non-dysplasia to those with low- to high-grade dysplasia 
including adenocarcinoma. In our cohort, 94% of  BE 
cases were the SSBE type (Table 2). Overexpression of  
p53 was the most important risk factor associated with 
dysplasia and adenocarcinoma (Table 3), and the level 
of  p53 expression was strongly related to the grade of  
dysplasia (Table 5). Several studies have shown that p53 
overexpression is increased in parallel with progression of  
histological changes from metaplasia to high-grade dyspla-
sia and adenocarcinoma[41-44]. In specimens obtained from 
surgical resection, expression of  p53 has been observed 
in the region of  adenocarcinoma as well as in adjacent 
dysplastic epithelia. In addition, in many cases, p53 gene 
mutations are found at the specific position resulting in a 
change in a specific amino acid residue in both adenocar-
cinoma and adjacent dysplastic epithelia[41,42]. These results 
suggest that p53 mutation, which is relatively uncommon 
in nondysplastic BE, is an important step in the progres-
sion to adenocarcinoma. Galipeau et al[45] have shown that 
inactivation of  p53 by mutation is strongly associated with 
progression to aneuploidy, possibly through the loss of  
p53-mediated apoptosis and cell-cycle arrest. The accumu-
lation of  these aneuploid cell populations has been shown 
to increase the risk of  developing adenocarcinoma[46].
The possible causal role of  p53 in tumorigenesis as 
well as tumor progression in BE has been postulated, 
based on histological evidence showing that p53 muta-
tions are more frequent in advanced stages in histology. 
Thus, it is important to address the hypothesis that p53 
Normal 
(n  = 45)
Low grade 
(n  = 14)
High grade and Ca 
(n  = 6)
p53 (-) 41 7 0
p53 (+)   4 4 4
p53 (++)   0 3 2
Pearson χ 2 test, P < 0.001.
Fujita M et al . Risk factors for Barrett’s epithelial dysplasia
SSBE: Short segment Barrett esophagus; BMI: Body mass index; LSBE: Long-segment Barrett’s esophagus; GERD: Gastroesophageal reflux disease; BP: 
Blood pressure; TG: Triglyceride; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; ALT: 
Alanine aminotransferase; AST: Aspartate aminotransferase; hs-CRP: High sensitivity C-reactive protein; GTP: Guanosinetriphosphate.
overexpression could predict progression of  nondysplas-
tic BE to adenocarcinoma. Younes et al[47] studied p53 
accumulation via immunohistochemistry in 54 patients 
with Barrett’s metaplasia, dysplasia, or adenocarcinoma; 
p53 accumulation increased in parallel with histologi-
cal progression from metaplasia to adenocarcinoma. 
Follow-up biopsies were available in 23 of  54 patients 
who had dysplasia in at least one biopsy specimen. They 
showed that only one of  21 (4.8%) patients who were 
all p53 negative in multiple biopsies had histological 
progression. In contrast, two of  three patients with p53-
positive biopsies progressed to high-grade dysplasia or 
intramucosal carcinoma (one patient was lost to follow-
up). These retrospective data suggest that p53 accumula-
tion increases the risk of  progression from low- to high-
grade dysplasia. These data are also consistent with our 
results showing that the level of  p53 expression was cor-
related with the grade of  dysplasia (Table 5), suggesting 
that mutated p53, which is expressed at an early stage, 
may stimulate the tumor progression in the metaplasia–
dysplasia-adenocarcinoma sequence of  BE.
We found a strong inverse association between H. 
pylori infection and dysplasia in BE (Table 2); the lowest 
prevalence of  H. pylori was observed in the high-grade 
dysplasia group (Table 4). Many studies have reported 
that the absence of  H. pylori colonization is associated 
with a greater likelihood of  developing esophageal 
dysplasia and adenocarcinoma[18,20-23]. Hence, H. pylori 
infection appears to have a protective effect against the 
development of  dysplasia and adenocarcinoma in BE. 
The mechanism through which the absence of  H. pylori 
colonization is associated with dysplasia in BE is un-
known, but there are several possibilities. First, H. pylori 
infection, in particular the more virulent Cag-A-positive 
strain, may lead to gastric atrophy resulting in suppres-
sion of  acid production; this may lower the risk of  BE 
and esophageal adenocarcinoma[24,25].
We analyzed the degree of  gastric atrophy according 
to the Kimura-Takemoto Classification[48] to confirm the 
association of  low acidity and BE dysplasia. We could 
not find any significant difference in the ratio of  atropy 
and distribution of  degree of  atrophy in normal indi-
viduals and patients with dysplasia (data not shown).
With regard to the possible outcome of  H. pylori 
eradication in BE, only a few studies have reported that 
the SSBE developed at 24 mo after H. pylori eradication, 
suggesting induction of  SSBE by the eradication[49]. In 
Japan, the prevalence of  H. pylori infection has been 
decreasing recently and the use of  H. pylori eradication 
therapy has flourished. For this reason, the incidence of  
BE and adenocarcinoma is likely to increase, and it is 
therefore important to determine risk factors for malig-
nant changes associated with the development of  dyspla-
sia and adenocarcinoma in BE after H. pylori eradication.
In our multivariate logistic analysis, diastolic blood 
pressure was an independent risk factor associated with 
progression of  BE from nondysplastic to dysplastic 
epithelium (Table 3). When we evaluated users of  anti-
hypertensive drugs, especially Ca antagonists, in normal 
individuals and patients with dysplasia, we could not find 
any significant difference (data not shown). Although 
this is believed to be the first report of  a relationship be-
tween diastolic blood pressure and dysplasia in BE, the 
underlying mechanisms are unclear.
When we analyzed the relationship variables among 
three categories such as patients with no dysplasia, low- 
or high- grade dysplasia by ANOVA, we detected no 
difference in diastolic BP (Table 4). We hypothesized the 
nonlinear relationship of  diastolic BP among the three 
groups shown in Table 4 as follows: if  the variables were 
associated with malignant potential of  Barrett’s epithe-
lium, it may show the linear relationship among the three 
groups, normal, low-grade and high-grade dysplasia. The 
diastolic BP, however, may be associated with the step 
such as columnar epithelial metaplasia, which is a rela-
tively early step of  transformation.
In our univariate analysis, body weight was extracted 
as a risk factor for dysplasia in BE, but BMI and waist 
circumference were not. In a Swedish study of  189 
cases of  newly diagnosed esophageal adenocarcinoma, a 
strong positive association was found between BMI and 
esophageal adenocarcinoma when controlling for GERD 
symptoms[11]. A study from the Veterans Association in 
the United States found that individuals with a BMI > 
30 had a fourfold greater risk for BE as compared with 
controls with a BMI < 25[7]. More recently, several stud-
ies have revealed that waist circumference, but not BMI, 
has a modest independent associations with the incidence 
BE, dysplasia and adenocarcinoma. Other studies have 
reported that a higher waist-to-hip ratio is associated with 
BE when data are adjusted for GERD symptoms and 
BMI[14,50]. In our multivariate logistic analysis, anthropo-
metric variables were not extracted as risk factors.
In conclusion we demonstrated that p53 overexpres-
sion, absence of  H. pylori infection, and low diastolic 
BP are independent risk factors associated with the 
dysplastic changes of  BE. Future studies such as well-
designed prospective studies are needed to elucidate the 
mechanisms underlying the association of  these risk 
factors with the sequence of  progression of  dysplasia 
to adenocarcinoma in BE and establish a high-rsk group 
progressing to adenocarcinoma.
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